Cytarabine is however not enough as a single chemotherapy in high risk MCL [28] and the combination treatment given in the MCL2 and MCL3 protocols could explain the lack of significant association between SAMHD1 expression and PFS or OS as here reported by us and recently also by others [23]. The gene discussed is SAMHD1; the disease is mantle cell lymphoma.